Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the <scp>IQVIA</scp> Medical Research Data UK database-Reference-Cited by-同舟云学术

Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the IQVIA Medical Research Data UK database

Published:2022-09-20 Issue:1 Volume:25 Page:156-165
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Subramanian Anuradhaa¹,Gokhale Krishna¹,Sainsbury Christopher¹^ORCID,Nirantharakumar Krishnarajah¹,Toulis Konstantinos A.¹²^ORCID

Affiliation:

1. Institute of Applied Health Research University of Birmingham Birmingham UK

2. Department of Endocrinology 424 General Military Hospital Thessaloniki Greece

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14858

Reference25 articles.

1. SGLT inhibitors in management of diabetes

2. Development of SGLT1 and SGLT2 inhibitors

3. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

4. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2

5. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!;Journal of Diabetes and its Complications;2023-07

2. Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis;Frontiers in Endocrinology;2023-05-23